.png)
The majority of early viral-vector-based therapeutics were developed within the context of rare diseases, either through direct administration to certain tissues or (in the case of late-stage or on-market oncology cell therapies) through ex vivo cell modification. In these contexts, small quantities of viral vectors were required, particularly as most therapies were still in the clinical stage of development. Now, with the shift beyond ultra-rare indications, viral-vector manufacturing requires rapid expansion to be able to address these diseases in the commercial space.
Comentários